European Commission Approves Secukinumab for Hidradenitis Suppurativa


The approval makes the drug Europe’s first and only interleukin (IL)-17A inhibitor approved for the condition.

A version of this article was originally published on DermatologyTimes. This version has been lightly edited.

The European Commission has approved secukinumab (Cosentyx; Novartis) for the treatment of hidradenitis suppurativa (HS) in adults with moderate to severe disease and a history of inadequate responses to systemic HS therapies, according to Novartis.1

Secukinumab is now the first and only approved interleukin (IL)-17A inhibitor approved for HS in the region. It is also the first new biologic treatment approved for HS in almost a decade.

The EC approval comes after positive phase 3 clinical trial datawas released earlier this year from the SUNSHINE and SUNRISE trials. The studies,2 which were identical, double-blind, placebo-controlled, randomized, and took place across 40 different countries, analyzed participants’ clinical responses to secukinumab, as well as the drug’s safety profile over time.

Prospective participants were patients ages 18 and older with a moderate to severe HS diagnosis for at least 1 year prior to the study’s start. Participants also had a history of prior inadequate responses to conventional systemic therapies. Exclusion criteria included a presence of 20 or more fistulae at baseline or had ongoing conditions requiring the use of prohibited medications, such as investigational treatments or systemic biological immunomodulating treatments.

The SUNSHINE trial had 541 patients screened and approved to participate ; 543 were approved to participate in the SUNRISE trial. For 52 weeks, participants received an assigned dose of 300 mg subcutaneous secukinumab administered every 2 weeks, 300 mg subcutaneous secukinumab administered every 4 weeks, or a subcutaneous placebo. Efficacy was defined as the achievement of HS clinical response.

In the SUNSHINE trial, researchers noted that when compared with participants in the placebo group, significantly more patients receiving 300 mg every 2 weeks had a HS clinical response. In the SUNRISE trial, significantly more patients in both secukinumab treatment groups had a HS clinical response compared to patients in the placebo group.

The most common reported adverse event was headache in both trials up to week 16.

“With only one currently approved treatment option, I see HS patients with a tremendous need for alternatives that reduce the disabling physical symptoms of HS, improve the emotional burden and help partially avoid invasive surgery, if treating early,” said Christos C. Zouboulis, MD, the president of the European Hidradenitis Suppurativa Foundation, director of the Departments of Dermatology, Venereology, Allergology and Immunology at Städtisches Klinikum Dessau, and the founding professor of Dermatology and Venereology at the Brandenburg Medical School in Germany.

"This expanded approval offers physicians an additional effective and, for dermatologists, familiar treatment choice that we can feel confident in prescribing for this complex and challenging disease,” he said.

The FDA is expected to make regulatory decisions for the drug later in the year.


  1. Novartis receives European approval for Cosentyx® asfirst and only IL-17A inhibitor for Hidradenitis Suppurativa. Novartis. June 1, 2023. Accessed June 1, 2023.,conventional%20systemic%20HS%20therapy7
  2. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. doi:10.1016/S0140-6736(23)00022-3

Related Videos
dr erin gillaspie
dr meredith mckean
Related Content
© 2023 MJH Life Sciences
All rights reserved.